Compare Abbott Laboratories (ABT) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs EPAM Systems Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while EPAM Systems Inc trades at $85.89 (market cap $4.68B). The key difference: Abbott Laboratories is far larger — about 35.7× EPAM Systems Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| ABT | EPAM | |
|---|---|---|
Market Cap | $166.94B | $4.68B |
Sector | Health | Technology |
52-Week High | $136.62 | $221.40 |
52-Week Low | $82.57 | $76.04 |
Enterprise Value | $193.69B | $3.93B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EPAM Systems trades at $89.55, up 1.45% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 12.48 and P/S of 0.87, while revenue grew to $5.46B in 2025. Recent news highlights EPAM's AI partnership successes and upcoming Q2 2026 earnings, with analyst consensus strongly favoring Buy ratings (64.87%) and a $130.90 price target suggesting significant upside.
The outlook remains positive given EPAM's solid fundamentals and AI-driven growth, but risks include competitive pressures in IT services and market volatility. Institutional sentiment is bullish, though technical indicators warn of near-term resistance. Investors should weigh the strong analyst support against recent price weakness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
